National Institutes of Health

InVivo Biosystems specializes in utilizing non-mammalian model organisms for biological and biomedical research. The company has developed a proprietary transgenic platform that allows for the genetic modification of simple microscopic animals, such as C. elegans and zebrafish, to serve as human proxies in disease research and drug discovery. This innovative approach provides researchers with valuable insights into genetic mutations and human health. By offering custom genome-edited models, InVivo Biosystems supports pharmaceutical, nutraceutical, and biotechnology companies, as well as academic institutions, in accelerating their research and drug development initiatives. The company aims to make research more affordable and accessible, ultimately contributing to the exploration of treatments for significant health challenges, including Alzheimer's disease, epilepsy, and cancer.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

Matter Bio is a biotechnology company dedicated to preserving genome integrity and enhancing longevity through the preservation of DNA information. The company aims to address the critical issue of information loss in the genome by assembling a team of expert scientists and executives. By focusing on mutation reversal, Matter Bio seeks to empower patients with the potential to improve their health and extend their lifespan. Through its innovative research services, the company strives to advance the understanding and application of genetic preservation techniques.

InVivo Biosystems specializes in utilizing non-mammalian model organisms for biological and biomedical research. The company has developed a proprietary transgenic platform that allows for the genetic modification of simple microscopic animals, such as C. elegans and zebrafish, to serve as human proxies in disease research and drug discovery. This innovative approach provides researchers with valuable insights into genetic mutations and human health. By offering custom genome-edited models, InVivo Biosystems supports pharmaceutical, nutraceutical, and biotechnology companies, as well as academic institutions, in accelerating their research and drug development initiatives. The company aims to make research more affordable and accessible, ultimately contributing to the exploration of treatments for significant health challenges, including Alzheimer's disease, epilepsy, and cancer.

RNAConnect provides enzymatic tools for visualizing and manipulating RNA.

Neurodon Corporation is focused on discovering and developing disease-modifying therapies for intractable diseases by addressing endoplasmic reticulum (ER) stress, a significant factor in cell dysfunction and death. The company's innovative approach utilizes first-in-class modulators to restore calcium levels in cells, enabling the creation of therapeutics for conditions such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and diabetes. Founded in 2019 and based in Crown Point, Indiana, Neurodon has advanced two candidates into IND-enabling studies, with plans to commence clinical trials in 2025. The company has raised over $11 million through various funding sources, including grants and partnerships, and is currently seeking additional funding to support its upcoming clinical studies. Neurodon’s unique platform technology positions it as a leader in addressing diseases linked to ER stress, with no direct competitors targeting the same mechanism of action.

Golden Helix has been delivering industry-leading bioinformatics solutions for the advancement of life science research and translational medicine for over 20 years. their innovative technologies and analytic services empower scientists and healthcare professionals at all levels to derive meaning from the rapidly increasing volumes of genomic data produced from microarrays and next-generation sequencing.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance understanding of biological functions and diseases. Unlike DNA sequencing, which offers limited insights, this next-generation platform provides deeper knowledge through single-molecule, massively parallel sequencing. By improving binding affinity and consistency, Glyphic's technology supports the creation of personalized and precision cancer vaccines tailored to individual patients. The company's innovative approach enables scientists and researchers to develop novel therapeutics and diagnostics, ultimately advancing the comprehension of human biology and disease mechanisms.

The Buck Institute is the nation’s first independent research facility focused solely on understanding the connection between aging and chronic disease. Their mission is to increase the healthy years of life. At the Buck Institute, world-class scientists work in a uniquely collaborative environment to understand how normal aging contributes to the development of conditions specifically associated with getting older such as Alzheimer’s and Parkinson’s diseases, cancer, stroke, osteoporosis, heart disease, diabetes, macular degeneration and glaucoma. Their interdisciplinary approach brings scientists from disparate fields together to develop diagnostic tests and treatments to prevent or delay these maladies. The stakes have never been higher. While it’s true that people are living longer, those “extra” years are often marked by disability and pain. In addition to personal hardship, there is also a cost to society. The financial burden of treating the chronic diseases of aging is expected to rise steadily as Baby Boomers get older. There is an urgency to Their mission.

Inherent Biosciences is a molecular diagnostics company focused on transforming the trial and error approach in medicine by leveraging insights from epigenetics. The company aims to provide clarity on complex health issues by identifying dysregulation across multiple genes and pathways, which informs personalized treatment strategies. Inherent Biosciences develops innovative therapies for a range of conditions, including pain, infertility, embryo quality, autism, rheumatoid arthritis, psoriatic arthritis, fetal heart disease, and COVID-19. By translating biological discoveries into actionable insights, the company seeks to enhance patient care and improve outcomes in various medical fields.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

TransCode Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on the discovery and development of microRNA (miRNA) therapeutics to treat metastatic diseases. Founded in 2016, the company is dedicated to combating cancer through the targeted eradication of metastatic tumor cells, primarily leveraging its proprietary TTX nanoparticle platform. Its lead therapeutic candidate, TTX-MC138, aims to inhibit microRNA-10b, a key biomarker associated with metastasis, and has shown promising preclinical validation. Additionally, TransCode is advancing a portfolio of innovative RNA therapeutic candidates designed to address the challenges of RNA delivery, thereby expanding therapeutic options for various genetic targets within oncology.

The Mount Sinai School of Medicine in New York, New York, one of the only schools in the nation with a distinctive Department of Medical Education that continually improves the quality of its teaching, offers students a variety of medical academics to shape them into compassionate assistants, professionals and industry leaders. The academics available at Mount Sinai include master's and PhD programs in areas like: * Science and Medicine * Patient Oriented Research Training and Leadership * Biomedical Sciences * Genetic Counseling * Clinical Research Besides its degree-granting programs, Mount Sinai also offers an extensive number of residencies and fellowships, some of which include: * Anesthesiology * Cardiology * Dental Medicine * Emergency Medicine * Hematology and Oncology College life at Mount Sinai is fully-immersed in the medical sciences. All your instruction, provided by medical professionals, will be delivered in a hospital setting, allowing you to familiarize yourself with the many resources and technology used in today's hospitals. Mount Sinai is also home to the Levy Library, which is fully-stocked with myriad medical resources, from journals to professional magazines to textbooks. Since each program has different admissions requirements, please contact Mount Sinai for more information on a program that interests you and your career goals. Tuition assistance is available to students through fellowship programs and Mount Sinai grants and scholarships. For more information federal sources of financial aid, please contact an aid advisor from the school.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

Allen Institute for Brain Science is a non-profit medical research organization dedicated to understanding the complexities of bioscience. The organization encompasses three entities, the Allen Institute for Brain Science, Allen Institute for Cell Science, and Paul G. Allen Frontiers Group. Its mission is to accelerate the understanding of how the brain works in health and disease. It creates useful public resources, drive technological and analytical advances, and discover fundamental brain properties through integration of experiments using a big science, team science, and open science approach. Allen Institute for Brain Science was founded on 2003 and is based in Seattle, Washington.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance understanding of biological functions and diseases. Unlike DNA sequencing, which offers limited insights, this next-generation platform provides deeper knowledge through single-molecule, massively parallel sequencing. By improving binding affinity and consistency, Glyphic's technology supports the creation of personalized and precision cancer vaccines tailored to individual patients. The company's innovative approach enables scientists and researchers to develop novel therapeutics and diagnostics, ultimately advancing the comprehension of human biology and disease mechanisms.

Oligomerix, Inc. is a biopharmaceutical company based in Bronx, New York, founded in 2006. It specializes in developing therapeutics for Alzheimer’s disease and related neurodegenerative disorders through innovative research on tau proteins. The company focuses on small molecule drug discovery, specifically targeting tau oligomers and developing tau protease inhibitors. In addition to small molecules, Oligomerix is involved in creating antibody fragments that serve as biomarkers to aid in drug development, diagnostics, and therapeutic applications. By leveraging its novel approaches to generate stable amyloid oligomers, Oligomerix aims to enhance target identification and validation, contributing to improved treatment options for various tauopathies, including progressive supranuclear palsy and frontotemporal dementia.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

Talus Bio is a biotech startup focused on drug discovery, particularly in the development of therapies targeting gene regulators for cancer treatment. The company utilizes a data-enabled platform that combines functional proteomics, automated biology, and machine learning to address the challenges associated with cancer transcription factors. Its proprietary MARMOT platform employs advanced techniques such as AI, quantitative proteomics, synthetic chemistry, and computational biology to design and analyze small-molecule drugs and proteins. This innovative approach aims to enhance drug development processes in the oncology sector, facilitating advancements in gene regulation and contributing to more effective cancer therapies.

Meridian Bioscience is an integrated life science company that develops, manufactures, and distributes clinical diagnostic test kits for gastrointestinal, viral, respiratory, and parasitic infectious diseases. The company specializes in molecular and immunological reagents, providing tools that support the discovery and diagnosis of various medical conditions. In addition to diagnostic test kits, Meridian offers bulk antigens, antibodies, PCR and qPCR reagents, nucleotides, and bioresearch reagents, serving researchers and other diagnostic manufacturers. Moreover, the company engages in contract development and manufacturing of proteins and other biologicals under cGMP conditions, catering to biopharmaceutical and biotechnology firms involved in drug and vaccine research. Meridian operates through three segments: U.S. Diagnostics, European Diagnostics, and Life Science, emphasizing its commitment to enhancing healthcare outcomes through innovative solutions.

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative cell and gene therapies aimed at treating hematologic cancers, solid tumors, and rare genetic diseases. The company has a diverse pipeline that includes gene therapy programs for rare genetic disorders and various chimeric antigen receptor (CAR) T cell therapies targeting both hematologic malignancies and solid tumors. Notable projects include MB-107, a gene therapy aimed at treating X-linked severe combined immunodeficiency, which is currently undergoing Phase 1/2 clinical trials. Other therapies under development include MB-102 for acute myeloid leukemia, MB-106 for B-cell lymphomas, and multiple CAR T programs targeting glioblastoma, prostate cancer, and pancreatic cancer. Mustang Bio also collaborates with institutions such as Nationwide Children’s Hospital and Beth Israel Deaconess Medical Center for research and development in gene editing and oncolytic viruses. Established in 2015 and headquartered in New York, Mustang Bio operates as a subsidiary of Fortress Biotech, Inc.

Diseases of the neuromuscular junction have profound health effects including paralysis, breathing and swallowing difficulties. Amplo Biotechnology plans to develop multiple, potentially curative, Adeno-Associated Viral (AAV) therapies for the neuromuscular junction with an initial focus on congenital myasthenic syndromes. Amplo’s lead program, AAV-Dok7, was developed by Professor Yuji Yamanashi's group of the Institute of Medical Science at the University of Tokyo, and is applicable to multiple rare, severe diseases.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

ID Genomics specializes in nucleotide sequence-based molecular diagnostics and epidemiologic analysis of microbial pathogens. We provide fast, high-resolution, large- or small-scale clonal identification for clinical microbiology, reference and academic research laboratories, using expanded multi-locus sequence typing (MLST), genome-wide polymorphism annotation, customized phylogenetic and genomic analysis and database creation.

TransCode Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on the discovery and development of microRNA (miRNA) therapeutics to treat metastatic diseases. Founded in 2016, the company is dedicated to combating cancer through the targeted eradication of metastatic tumor cells, primarily leveraging its proprietary TTX nanoparticle platform. Its lead therapeutic candidate, TTX-MC138, aims to inhibit microRNA-10b, a key biomarker associated with metastasis, and has shown promising preclinical validation. Additionally, TransCode is advancing a portfolio of innovative RNA therapeutic candidates designed to address the challenges of RNA delivery, thereby expanding therapeutic options for various genetic targets within oncology.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

Cytonus Therapeutics, Inc. is a biotechnology company founded in 2018 and based in Columbus, Ohio. The company focuses on developing immune-oncology and gene therapies aimed at treating devastating and rare diseases. Cytonus combines artificial intelligence-driven drug discovery with a unique delivery system known as Cargocyte, which utilizes synthetic biology for precision treatment. The company's mission centers on addressing immune-related disorders through innovative approaches that enable targeted delivery and in vivo production of first-in-class therapeutics.

Inso Biosciences is an early-stage biotechnology company focused on developing innovative hardware platforms and tools for genomic sample handling. Utilizing patented microfluidic technology originally created at Cornell University, the company specializes in high-efficiency processing of cellular material. Inso Biosciences aims to enhance applications in long-read DNA extraction, multiomic sample processing, and pathogen surveillance. Their platform facilitates the separation and isolation of cellular components, thereby supporting healthcare and biotech companies in their biological sample preparation needs.

HDT Bio is a clinical-stage biotechnology company focused on developing RNA vaccines and therapeutics to combat infectious diseases and cancer. Utilizing its innovative LION formulation technology, the company creates ribonucleic acid-based products that enhance the delivery and stability of nucleic acids through various administration routes. HDT Bio’s offerings include self-amplifying RNA vaccines and innate immune agonist therapeutics, which aim to activate innate immunity, amplify adaptive immune responses, and disrupt tumor tight junctions. The company's mission is to advance immunotherapy technologies in a cost-effective manner, addressing critical healthcare needs in both developed and low- to middle-income countries, particularly in the fight against some of the world's most dangerous infectious diseases.

Cytonus Therapeutics, Inc. is a biotechnology company founded in 2018 and based in Columbus, Ohio. The company focuses on developing immune-oncology and gene therapies aimed at treating devastating and rare diseases. Cytonus combines artificial intelligence-driven drug discovery with a unique delivery system known as Cargocyte, which utilizes synthetic biology for precision treatment. The company's mission centers on addressing immune-related disorders through innovative approaches that enable targeted delivery and in vivo production of first-in-class therapeutics.

Meridian Bioscience is an integrated life science company that develops, manufactures, and distributes clinical diagnostic test kits for gastrointestinal, viral, respiratory, and parasitic infectious diseases. The company specializes in molecular and immunological reagents, providing tools that support the discovery and diagnosis of various medical conditions. In addition to diagnostic test kits, Meridian offers bulk antigens, antibodies, PCR and qPCR reagents, nucleotides, and bioresearch reagents, serving researchers and other diagnostic manufacturers. Moreover, the company engages in contract development and manufacturing of proteins and other biologicals under cGMP conditions, catering to biopharmaceutical and biotechnology firms involved in drug and vaccine research. Meridian operates through three segments: U.S. Diagnostics, European Diagnostics, and Life Science, emphasizing its commitment to enhancing healthcare outcomes through innovative solutions.

Coral Genomics, Inc. is a biotechnology company based in San Francisco, California, founded in 2018. The company specializes in optimizing drug development and deployment through the use of genomic data derived from patients. Coral Genomics focuses on creating new clinical tests that assist healthcare providers in streamlining prior authorization processes and selecting effective medications tailored to individual patients, particularly those with autoimmune conditions such as Inflammatory Bowel Disease and Rheumatoid Arthritis. Additionally, the company has identified a distinct population of non-responder patients and collaborates with drug developers to address their unmet medical needs.

Meridian Bioscience is an integrated life science company that develops, manufactures, and distributes clinical diagnostic test kits for gastrointestinal, viral, respiratory, and parasitic infectious diseases. The company specializes in molecular and immunological reagents, providing tools that support the discovery and diagnosis of various medical conditions. In addition to diagnostic test kits, Meridian offers bulk antigens, antibodies, PCR and qPCR reagents, nucleotides, and bioresearch reagents, serving researchers and other diagnostic manufacturers. Moreover, the company engages in contract development and manufacturing of proteins and other biologicals under cGMP conditions, catering to biopharmaceutical and biotechnology firms involved in drug and vaccine research. Meridian operates through three segments: U.S. Diagnostics, European Diagnostics, and Life Science, emphasizing its commitment to enhancing healthcare outcomes through innovative solutions.

Coda Biotherapeutics, Inc. is a biotechnology company focused on developing innovative treatments for neurological disorders. The company specializes in chemogenetic technology, which allows for precise modulation of neuronal activity through gene therapy. By using viral vectors, Coda Biotherapeutics introduces engineered neurotransmitter receptors into specific neuronal populations. These receptors are designed to respond to a proprietary small molecule, enabling targeted control of neuronal functions. This approach aims to effectively treat conditions such as neuropathic pain, epilepsy, and movement disorders, offering a potential advancement over traditional therapies. Founded in 2014, Coda Biotherapeutics is headquartered in San Francisco, California.

Cytonus Therapeutics, Inc. is a biotechnology company founded in 2018 and based in Columbus, Ohio. The company focuses on developing immune-oncology and gene therapies aimed at treating devastating and rare diseases. Cytonus combines artificial intelligence-driven drug discovery with a unique delivery system known as Cargocyte, which utilizes synthetic biology for precision treatment. The company's mission centers on addressing immune-related disorders through innovative approaches that enable targeted delivery and in vivo production of first-in-class therapeutics.

Cytonus Therapeutics, Inc. is a biotechnology company founded in 2018 and based in Columbus, Ohio. The company focuses on developing immune-oncology and gene therapies aimed at treating devastating and rare diseases. Cytonus combines artificial intelligence-driven drug discovery with a unique delivery system known as Cargocyte, which utilizes synthetic biology for precision treatment. The company's mission centers on addressing immune-related disorders through innovative approaches that enable targeted delivery and in vivo production of first-in-class therapeutics.

Phase Genomics, Inc. is a biotechnology company based in Seattle, Washington, founded in 2015. The company specializes in developing innovative technology for genome assembly and metagenome deconvolution, focusing on its ProxiMeta Hi-C platform. This platform empowers researchers in various fields, including agriculture, human health, and industrial biology, by enabling the cultivation-independent assembly of bacterial genomes. By exploiting the structure of DNA, Phase Genomics aims to provide scientists with the most complete and accurate genomes and metagenomes possible, facilitating transformative discoveries and advancements in their respective areas of study.

Neurodon Corporation is focused on discovering and developing disease-modifying therapies for intractable diseases by addressing endoplasmic reticulum (ER) stress, a significant factor in cell dysfunction and death. The company's innovative approach utilizes first-in-class modulators to restore calcium levels in cells, enabling the creation of therapeutics for conditions such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and diabetes. Founded in 2019 and based in Crown Point, Indiana, Neurodon has advanced two candidates into IND-enabling studies, with plans to commence clinical trials in 2025. The company has raised over $11 million through various funding sources, including grants and partnerships, and is currently seeking additional funding to support its upcoming clinical studies. Neurodon’s unique platform technology positions it as a leader in addressing diseases linked to ER stress, with no direct competitors targeting the same mechanism of action.

Mammoth Biosciences, Inc. is a biotechnology company based in South San Francisco, California, that focuses on developing innovative CRISPR solutions for a variety of applications. The company offers DETECTR™, a diagnostic platform that identifies specific nucleic acids in samples, aiding in the detection of diseases such as bacterial infections, cancer, and viral infections. Additionally, Mammoth Biosciences provides CRISPR-Cas systems for genome editing, targeting therapeutic areas including immuno-oncology, autoimmune diseases, and liver diseases. By harnessing proprietary ultracompact proteins and leveraging advanced research and development, Mammoth aims to create affordable point-of-care tests and enhance diagnostics across healthcare, agriculture, and environmental monitoring. Co-founded by CRISPR pioneer Jennifer Doudna, the company has attracted significant investment from institutional and individual backers.

Mesa Biotech simplifies DNA testing. The Mesa Biotech team has achieved a dramatic simplification in the complexity of DNA and RNA molecular testing. Mesa Biotech is based in sunny San Diego, California with a satellite testing laboratory in Santa Fe, New Mexico.

Cytonus Therapeutics, Inc. is a biotechnology company founded in 2018 and based in Columbus, Ohio. The company focuses on developing immune-oncology and gene therapies aimed at treating devastating and rare diseases. Cytonus combines artificial intelligence-driven drug discovery with a unique delivery system known as Cargocyte, which utilizes synthetic biology for precision treatment. The company's mission centers on addressing immune-related disorders through innovative approaches that enable targeted delivery and in vivo production of first-in-class therapeutics.

Fauna Bio Incorporated is a biotechnology company based in San Francisco, California, founded in 2018. It specializes in developing a cross-mammal drug discovery platform aimed at treating human diseases, including heart disease and neurodegenerative disorders. By studying the mechanisms that allow certain animals, such as hibernating and deep-diving species, to withstand extreme conditions, Fauna Bio seeks to uncover insights that can enhance human health. The company utilizes animal genomics, transcriptomics, metabolomics, and proteomics data from a diverse range of species to identify novel drug targets and facilitate pre-clinical and early clinical testing of new therapeutics. Through its innovative approach, Fauna Bio aims to improve recovery from serious medical events like trauma, heart attacks, and strokes.

DiamiR is mission is to build a leading molecular diagnostics company focused on developing minimally invasive solutions for early detection and monitoring of brain and synaptic health conditions, including mild cognitive impairment and Alzheimer’s disease, to enable earlier intervention and better planning of care.

Precision Virologics, Inc. is a biotechnology company focused on developing biologically targeted vaccines for emerging infectious diseases, including Zika. Established in 2016 and headquartered in Saint Louis, Missouri, the company utilizes an innovative technology based on adenoviral vectors that incorporate camelid antibodies aimed at activated dendritic cells. This approach allows for the precise delivery of proprietary antigen epitopes to target pathogens and offers significant advantages, such as reduced cross-reactivity among flaviviruses and enhanced potency. In addition to its Zika vaccine candidate, PV-ZIKV, Precision Virologics also aims to address other infectious diseases, including chikungunya and dengue, by harnessing its advanced vaccine development capabilities.

The Clinical Pharmacogenetics Implementation Consortium (CPIC®) is an international consortium of individual volunteers and a small dedicated staff who are interested in facilitating use of pharmacogenetic tests for patient care. One barrier to implementation of pharmacogenetic testing in the clinic is the difficulty in translating genetic laboratory test results into actionable prescribing decisions for affected drugs. CPIC’s goal is to address this barrier to clinical implementation of pharmacogenetic tests by creating, curating, and posting freely available, peer-reviewed, evidence-based, updatable, and detailed gene/drug clinical practice guidelines (click here for all CPIC publications). CPIC guidelines follow standardized formats, include systematic grading of evidence and clinical recommendations, use standardized terminology, are peer-reviewed, and are published in a leading journal (in partnership with Clinical Pharmacology and Therapeutics) with simultaneous posting to cpicpgx.org, where they are regularly updated.

Salk Institute for Biological Studies conducts research on molecular biology and genetics, neurosciences, and plant biology. The research is conducted under the guidance of 59 faculty investigators and more than 850 scientific staff, including visiting scientists, postdoctoral fellows, and graduate students. The institute’s operates to identify therapies and treatments for a range of diseases such as cancer, AIDS, Alzheimer's disease, cardiovascular disorders, anomalies of the brain, and birth defects. Six key areas represent strategic research priorities: chemistry and proteomics, stem cell biology, cell biology, regulatory biology, metabolic research, and computational and theoretical biology. The Institute has trained more than 2,700 scientists, out of which five have won Nobel prizes. Salk is home to nine Howard Hughes Medical Investigators and 14 members of the National Academy of Sciences. NCI Cancer Center, Crick-Jacobs Center, Glenn Center for Aging Research, Helmsley Center for Genomic Medicine, Waitt Advanced Biophotonics Center, and Glenn Center for Aging Research are some of the research centers operated by Salk Institute for Biological Studies. The Salk Institute for Biological Studies was established in the 1960s by Jonas Salk and is based in California, United States.

Quadrant Biosciences Inc. is a life sciences company focused on developing epigenetic diagnostic solutions and biomarker technologies aimed at addressing significant healthcare challenges, particularly in the early identification of neurological disorders such as Autism Spectrum Disorder, concussion, and Parkinson's Disease. Founded in 2015 and based in Syracuse, New York, the company has established collaborative research relationships with various institutions to explore innovative diagnostic and therapeutic solutions. Quadrant Biosciences leverages its expertise in RNA analysis to enhance healthcare delivery and has also contributed to addressing health issues related to the COVID-19 pandemic. The company aims to improve lives through its commitment to advancing molecular diagnostic tools.

Precision Virologics, Inc. is a biotechnology company focused on developing biologically targeted vaccines for emerging infectious diseases, including Zika. Established in 2016 and headquartered in Saint Louis, Missouri, the company utilizes an innovative technology based on adenoviral vectors that incorporate camelid antibodies aimed at activated dendritic cells. This approach allows for the precise delivery of proprietary antigen epitopes to target pathogens and offers significant advantages, such as reduced cross-reactivity among flaviviruses and enhanced potency. In addition to its Zika vaccine candidate, PV-ZIKV, Precision Virologics also aims to address other infectious diseases, including chikungunya and dengue, by harnessing its advanced vaccine development capabilities.

Celldom, Inc. is a research tools company based in Durham, North Carolina, established in 2016. It specializes in single-cell analysis technology aimed at enhancing research, drug discovery, and development by revealing the diversity within cell populations. The company's flagship product, the TrapTx Analyzer System, integrates phenotypic and genomic data on a large scale, allowing for the identification and characterization of rare cells that are crucial in various biological pathways and diseases. Celldom focuses on applications in oncology, immunology, and stem cell biology, providing innovative solutions that enable researchers to automate the analysis of cellular heterogeneity effectively.

Neurodon Corporation is focused on discovering and developing disease-modifying therapies for intractable diseases by addressing endoplasmic reticulum (ER) stress, a significant factor in cell dysfunction and death. The company's innovative approach utilizes first-in-class modulators to restore calcium levels in cells, enabling the creation of therapeutics for conditions such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and diabetes. Founded in 2019 and based in Crown Point, Indiana, Neurodon has advanced two candidates into IND-enabling studies, with plans to commence clinical trials in 2025. The company has raised over $11 million through various funding sources, including grants and partnerships, and is currently seeking additional funding to support its upcoming clinical studies. Neurodon’s unique platform technology positions it as a leader in addressing diseases linked to ER stress, with no direct competitors targeting the same mechanism of action.

Mission Bio, Inc. is a biotechnology company that specializes in tools for studying cellular heterogeneity in human health and life sciences. The company has developed the Tapestri Platform, the first single-cell multi-omics platform, which allows for the simultaneous analysis of genotype and phenotype from the same cell. This platform utilizes proprietary microfluidic droplet technology to enable precise detection of genomic variability at single-cell resolution, facilitating research in various applications, including oncology, blood cancers, solid tumors, and genome editing. Additionally, Mission Bio offers Tapestri Designer, a cloud-based tool for creating customized single-cell DNA panels, further enhancing its capabilities in targeted molecular analysis. Founded in 2011 and based in South San Francisco, California, the company was previously known as Torrent Bio, Inc. before rebranding in 2013.

Intact Genomics is a world leader in large DNA fragment cloning and metagenomic technologies. We have dedicated scientists and state of the art equipment all housed in a modern facility, located in the Helix Center Biotech Incubator, next to Monsanto Headquarters, Donald Danforth Plant Science Center, and close to Washington University in St. Louis

Scripps Translational Science Institute works to translate the latest advances in genomics into new diagnostics and treatments. In collaboration with Scripps Genomic Medicine, STSI researchers have collected DNA to generate a comprehensive human DNA bank. These samples could help identify genetic markers for cardiovascular disease, breast, colon and prostate cancers. and other conditions. STSI and Scripps Genomic Medicine investigators have also partnered with Affymetrix, Microsoft, and Navigenics to determine whether personal genomic testing motivates people to make positive lifestyle changes.

Scripps Research is a prominent independent, not-for-profit organization dedicated to advancing biomedical research aimed at enhancing human health. Established from the Scripps Metabolic Clinic in 1924, it has grown into one of the largest institutions of its kind, employing around 3,000 individuals across its campuses in La Jolla, California, and Jupiter, Florida. The institute is recognized for its significant contributions to the biomedical sciences, including the development of new treatments for various diseases such as cancer, rheumatoid arthritis, and hemophilia. Scripps Research is home to renowned scientists, including three Nobel laureates, who engage in cutting-edge research. Additionally, its graduate program in biology and chemistry is highly regarded, consistently ranking among the top ten programs in the United States.

Sangamo Therapeutics is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company's product pipeline includes Hemophilia, Central Nervous System, HIV, Lysosomal Storage Disorders, and Hemoglobinopathies.

SolveBio specializes in genomic intelligence, providing a platform that facilitates the integration and management of genomic data for pharmaceutical, biotech, and diagnostic organizations. By enabling these entities to connect and utilize both internal and external genomic information, SolveBio supports innovation in precision medicine and advances human health. The platform allows clients to access and distribute genomic reference data at scale, creating a dynamic interface that enhances the use of third-party information assets. This approach empowers organizations to drive discovery and improve decision-making in the rapidly evolving field of genomics.

Allen Institute for Brain Science is a non-profit medical research organization dedicated to understanding the complexities of bioscience. The organization encompasses three entities, the Allen Institute for Brain Science, Allen Institute for Cell Science, and Paul G. Allen Frontiers Group. Its mission is to accelerate the understanding of how the brain works in health and disease. It creates useful public resources, drive technological and analytical advances, and discover fundamental brain properties through integration of experiments using a big science, team science, and open science approach. Allen Institute for Brain Science was founded on 2003 and is based in Seattle, Washington.

Scripps Research is a prominent independent, not-for-profit organization dedicated to advancing biomedical research aimed at enhancing human health. Established from the Scripps Metabolic Clinic in 1924, it has grown into one of the largest institutions of its kind, employing around 3,000 individuals across its campuses in La Jolla, California, and Jupiter, Florida. The institute is recognized for its significant contributions to the biomedical sciences, including the development of new treatments for various diseases such as cancer, rheumatoid arthritis, and hemophilia. Scripps Research is home to renowned scientists, including three Nobel laureates, who engage in cutting-edge research. Additionally, its graduate program in biology and chemistry is highly regarded, consistently ranking among the top ten programs in the United States.

Circulomics is a biotechnology company based in Maryland, operating within the IMET's Harbor Launch Incubator. The company has secured nearly $8 million in funding from the National Institutes of Health and Maryland TEDCO to create advanced platforms for nucleic acid sample preparation, microRNA profiling, and single molecule analysis. These innovations aim to enhance the research and clinical applications of genomics technologies, facilitating processes from sequencing to expression profiling and biomarker analysis. Circulomics has developed a single molecule analysis system that optimizes the genomics workflow, improving sample characterization prior to sequencing and critical studies, thereby supporting cancer diagnosis and analysis.

Circulomics is a biotechnology company based in Maryland, operating within the IMET's Harbor Launch Incubator. The company has secured nearly $8 million in funding from the National Institutes of Health and Maryland TEDCO to create advanced platforms for nucleic acid sample preparation, microRNA profiling, and single molecule analysis. These innovations aim to enhance the research and clinical applications of genomics technologies, facilitating processes from sequencing to expression profiling and biomarker analysis. Circulomics has developed a single molecule analysis system that optimizes the genomics workflow, improving sample characterization prior to sequencing and critical studies, thereby supporting cancer diagnosis and analysis.

Celldom, Inc. is a research tools company based in Durham, North Carolina, established in 2016. It specializes in single-cell analysis technology aimed at enhancing research, drug discovery, and development by revealing the diversity within cell populations. The company's flagship product, the TrapTx Analyzer System, integrates phenotypic and genomic data on a large scale, allowing for the identification and characterization of rare cells that are crucial in various biological pathways and diseases. Celldom focuses on applications in oncology, immunology, and stem cell biology, providing innovative solutions that enable researchers to automate the analysis of cellular heterogeneity effectively.

23andMe, Inc. is a consumer genetics company based in Sunnyvale, California, founded in 2006. It offers DNA analysis services through home-based saliva collection kits, enabling consumers to explore their genetic ancestry, traits, and health predispositions. The company provides various services, including Health + Ancestry, which delivers insights into ancestry and genetic health risks, and Ancestry + Traits, which offers an ancestry breakdown along with reports on over 30 traits. Additionally, 23andMe markets its data to researchers and scientists, providing them with categorized and searchable genetic information. The firm aims to enhance understanding of the human genome and its implications for health and ancestry. Through its consumer and research services, 23andMe seeks to make genetic information accessible and meaningful to individuals and professionals alike.

Scripps Research is a prominent independent, not-for-profit organization dedicated to advancing biomedical research aimed at enhancing human health. Established from the Scripps Metabolic Clinic in 1924, it has grown into one of the largest institutions of its kind, employing around 3,000 individuals across its campuses in La Jolla, California, and Jupiter, Florida. The institute is recognized for its significant contributions to the biomedical sciences, including the development of new treatments for various diseases such as cancer, rheumatoid arthritis, and hemophilia. Scripps Research is home to renowned scientists, including three Nobel laureates, who engage in cutting-edge research. Additionally, its graduate program in biology and chemistry is highly regarded, consistently ranking among the top ten programs in the United States.

Inova Translational Medicine Institute (ITMI) is a not-for-profit research institute that applies genomic and clinical information from individuals to develop innovative methods for personalized healthcare. ITMI is part of Inova Center for Personalized Health (ICPH), which connects researchers, clinicians, and consumers to integrate genomic research for patient care, prevention, and wellness. This approach enables individuals to live longer and transforms healthcare from reactive to predictive. Research studies at ITMI generate a large genomic and clinical data set that can be used by researchers in a variety of fields, from computational biology to psychology, and biomedical research applications. ITMI’s utilizes genomic information from an individual to understand the onset of disease, leading to the implementation of preventative medicine, and to increase successful outcomes while reducing adverse reactions to treatment.

Intact Genomics is a world leader in large DNA fragment cloning and metagenomic technologies. We have dedicated scientists and state of the art equipment all housed in a modern facility, located in the Helix Center Biotech Incubator, next to Monsanto Headquarters, Donald Danforth Plant Science Center, and close to Washington University in St. Louis

ID Genomics specializes in nucleotide sequence-based molecular diagnostics and epidemiologic analysis of microbial pathogens. We provide fast, high-resolution, large- or small-scale clonal identification for clinical microbiology, reference and academic research laboratories, using expanded multi-locus sequence typing (MLST), genome-wide polymorphism annotation, customized phylogenetic and genomic analysis and database creation.

Stemina Biomarker Discovery, Inc., a metabolomics company, focuses on the discovery, development, and commercialization of molecular biomarkers to improve drug safety and human health. The company works on collaborative research projects and joint development agreements with strategic partners to develop drugs, identify targets, and discover molecular biomarkers for the diagnosis of diseases and customized treatment. It provides metabolomics and mass spectrometry services, as well as develops diagnostic biomarkers. The company's cell-based assays arise from the strategic convergence of technologies, such as human embryonic stem (hES) cells and metabolomics. It uses mass spectrometry to analyze the small molecules secreted by hES, heart, and neural cells in response to drugs, injury, or disease. Stemina Biomarker Discovery, Inc. was founded in 2006 and is based in Madison, Wisconsin.

The Vermont Genetics Network (VGN) is funded by a five-year, $16.5 million award from the National Center for Research Resources (NCRR), and is part of a National Institutes of Health (NIH) initiative called IDeA Networks of Biomedical Research Excellence (INBRE). Under the direction of Dr. Judith Van Houten, the VGN, which links scientists at Castleton State College, Johnson State College, Middlebury College, Norwich University and St. Michael's College to resources at UVM, is designed to provide funding for research, equipment and technology necessary to enhance competitiveness for national funding for genetics research. Other aims of the project include increasing the number of undergraduates who go on to biomedical careers from the baccalaureate colleges, to provide and support bioinformatics capability in the state, and to increase the diversity of biomedical scientists.

Scripps Research is a prominent independent, not-for-profit organization dedicated to advancing biomedical research aimed at enhancing human health. Established from the Scripps Metabolic Clinic in 1924, it has grown into one of the largest institutions of its kind, employing around 3,000 individuals across its campuses in La Jolla, California, and Jupiter, Florida. The institute is recognized for its significant contributions to the biomedical sciences, including the development of new treatments for various diseases such as cancer, rheumatoid arthritis, and hemophilia. Scripps Research is home to renowned scientists, including three Nobel laureates, who engage in cutting-edge research. Additionally, its graduate program in biology and chemistry is highly regarded, consistently ranking among the top ten programs in the United States.

Igenica, Inc. is a biotherapeutic company based in Burlingame, California, dedicated to the discovery and development of antibodies and antibody-drug conjugates (ADCs) for cancer treatment. Founded in 2008, Igenica specializes in immunotherapies and functional antibodies designed to target tumors effectively. The company's notable products include IGN523, a humanized monoclonal antibody aimed at treating various hematologic and solid tumors; IGN786, an ADC; and IGN381, which targets immune checkpoints that complement existing therapies in the tumor microenvironment. Igenica has established a strategic oncology research agreement with MedImmune and is supported by a group of prominent life science investors, including The Column Group and OrbiMed. The company operates as a subsidiary of Pierre Fabre Medicament SA, with a leadership team that has significant experience in antibody drug discovery and commercialization.

The J. Craig Venter Institute is a prominent organization in genomic research, established in October 2006 through the merger of several institutions, including The Institute for Genomic Research and The Center for the Advancement of Genomics. With over 400 scientists and staff, the Institute operates from two primary locations in Rockville, Maryland, and San Diego, California, encompassing more than 250,000 square feet of laboratory space. The Institute's research initiatives span a wide range of topics, including genomic medicine, infectious diseases, mammalian genomics, microbial and environmental genomics, and synthetic biology. Notable achievements include the sequencing of the first free-living organism and significant contributions to the human genome project. Recent projects have involved sequencing microbial flora in human environments and discovering millions of new genes from ocean sampling expeditions. The Institute is also actively engaged in creating synthetic organisms and studying the evolution of infectious disease agents, aiming to enhance understanding and treatment of various diseases affecting global health.

Oligomerix, Inc. is a biopharmaceutical company based in Bronx, New York, founded in 2006. It specializes in developing therapeutics for Alzheimer’s disease and related neurodegenerative disorders through innovative research on tau proteins. The company focuses on small molecule drug discovery, specifically targeting tau oligomers and developing tau protease inhibitors. In addition to small molecules, Oligomerix is involved in creating antibody fragments that serve as biomarkers to aid in drug development, diagnostics, and therapeutic applications. By leveraging its novel approaches to generate stable amyloid oligomers, Oligomerix aims to enhance target identification and validation, contributing to improved treatment options for various tauopathies, including progressive supranuclear palsy and frontotemporal dementia.

Akonni Biosystems, Inc. is a biotechnology company based in Frederick, Maryland, specializing in molecular diagnostics. Founded in 2003, the company develops and manufactures integrated diagnostic systems aimed at clinical and life science research markets. Its key product, the TruDiagnosis platform, allows for point-of-care testing of infectious diseases, while TruTip kits assist in DNA and RNA extraction. The company also offers TruArray tests for multiplexed molecular diagnostics, which analyze clinical samples such as blood, saliva, and urine. Akonni's technology is utilized in diagnosing a range of conditions, including infectious diseases, oncology, and genetic disorders. Their innovative systems leverage advanced methods like 3D gel drop microarray technology for effective detection of various health-related targets.

The Jackson Laboratory conducts mammalian genetics research in the United States. It offers scientific services and genetic resources to laboratories internationally, and educates students of various ages through courses, internships, and programs. The company also provides scientific resources, techniques, software, and data to scientists internationally. It offers high school internships, pre and post-doctoral opportunities, and collaborative education programs. The company discovers genetic basis for preventing, treating, and curing human diseases in the areas of cancers, computational biology and bioinformatics, developmental and reproductive biology, immunology, metabolic diseases, and neurobiology. In addition, it offers mouse breeding and research services designed for mouse-based biomedical research community, such as breeding and colony management, cryopreservation and recovery, phenotyping and efficacy testing, genetic research services, and study-ready induced models. The Jackson Laboratory was founded in 1929 and is based in Bar Harbor, Maine. It has a facility in California.

Circulomics is a biotechnology company based in Maryland, operating within the IMET's Harbor Launch Incubator. The company has secured nearly $8 million in funding from the National Institutes of Health and Maryland TEDCO to create advanced platforms for nucleic acid sample preparation, microRNA profiling, and single molecule analysis. These innovations aim to enhance the research and clinical applications of genomics technologies, facilitating processes from sequencing to expression profiling and biomarker analysis. Circulomics has developed a single molecule analysis system that optimizes the genomics workflow, improving sample characterization prior to sequencing and critical studies, thereby supporting cancer diagnosis and analysis.

REGENXBIO Inc. is a clinical-stage biotechnology company specializing in gene therapy aimed at addressing genetic defects and enabling cells to produce therapeutic proteins and antibodies. The company utilizes its proprietary NAV Technology Platform, which involves recombinant adeno-associated virus vectors for gene delivery. REGENXBIO’s lead candidate, RGX-314, is currently in Phase I/IIa clinical trials for the treatment of wet age-related macular degeneration. Additional product candidates under development include RGX-121 for mucopolysaccharidosis type II, RGX-111 for mucopolysaccharidosis type I, RGX-181 for late infantile neuronal ceroid lipofuscinosis type II, and RGX-501 for homozygous familial hypercholesterolemia. Beyond its own product candidates, REGENXBIO also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies and has a collaboration agreement with Neurimmune AG to develop vectorized antibodies for neurodegenerative diseases. Founded in 2008 and headquartered in Rockville, Maryland, the company was previously known as ReGenX Biosciences, LLC before rebranding in 2014.

Natera, Inc. is a diagnostic company that specializes in preconception and prenatal genetic testing services. Its primary offerings include the Panorama test, which is a non-invasive prenatal test that screens for chromosomal abnormalities in a fetus through a blood sample from the mother, and the Vistara test, designed to identify single-gene disorders. Additionally, Natera provides Horizon carrier screening to determine genetic disease carrier status and Spectrum, which analyzes chromosomal anomalies during in vitro fertilization. The company also offers Anora, a test for analyzing fetal chromosomes to investigate miscarriage causes, and non-invasive paternity testing. Its Signatera product utilizes circulating tumor DNA technology to monitor cancer recurrence. Natera markets its tests through a direct sales force and a network of approximately 100 laboratory and distribution partners both domestically and internationally. The company, founded in 2003 and headquartered in San Carlos, California, maintains partnerships with BGI Genomics and Foundation Medicine for the development of genetic testing assays.

Akonni Biosystems, Inc. is a biotechnology company based in Frederick, Maryland, specializing in molecular diagnostics. Founded in 2003, the company develops and manufactures integrated diagnostic systems aimed at clinical and life science research markets. Its key product, the TruDiagnosis platform, allows for point-of-care testing of infectious diseases, while TruTip kits assist in DNA and RNA extraction. The company also offers TruArray tests for multiplexed molecular diagnostics, which analyze clinical samples such as blood, saliva, and urine. Akonni's technology is utilized in diagnosing a range of conditions, including infectious diseases, oncology, and genetic disorders. Their innovative systems leverage advanced methods like 3D gel drop microarray technology for effective detection of various health-related targets.

Akonni Biosystems, Inc. is a biotechnology company based in Frederick, Maryland, specializing in molecular diagnostics. Founded in 2003, the company develops and manufactures integrated diagnostic systems aimed at clinical and life science research markets. Its key product, the TruDiagnosis platform, allows for point-of-care testing of infectious diseases, while TruTip kits assist in DNA and RNA extraction. The company also offers TruArray tests for multiplexed molecular diagnostics, which analyze clinical samples such as blood, saliva, and urine. Akonni's technology is utilized in diagnosing a range of conditions, including infectious diseases, oncology, and genetic disorders. Their innovative systems leverage advanced methods like 3D gel drop microarray technology for effective detection of various health-related targets.

Akonni Biosystems, Inc. is a biotechnology company based in Frederick, Maryland, specializing in molecular diagnostics. Founded in 2003, the company develops and manufactures integrated diagnostic systems aimed at clinical and life science research markets. Its key product, the TruDiagnosis platform, allows for point-of-care testing of infectious diseases, while TruTip kits assist in DNA and RNA extraction. The company also offers TruArray tests for multiplexed molecular diagnostics, which analyze clinical samples such as blood, saliva, and urine. Akonni's technology is utilized in diagnosing a range of conditions, including infectious diseases, oncology, and genetic disorders. Their innovative systems leverage advanced methods like 3D gel drop microarray technology for effective detection of various health-related targets.

Diffinity Genomics, Inc., a biotechnology company, develops DNA testing products for the life sciences industry. The company offers RapidTip, a single-use functional pipette tip for purifying polymerase chain reaction amplicons. It also develops products for nucleic acid isolation and analysis. Diffinity Genomics, Inc. was founded in 2005 and is based in West Henrietta, New York.

Akonni Biosystems, Inc. is a biotechnology company based in Frederick, Maryland, specializing in molecular diagnostics. Founded in 2003, the company develops and manufactures integrated diagnostic systems aimed at clinical and life science research markets. Its key product, the TruDiagnosis platform, allows for point-of-care testing of infectious diseases, while TruTip kits assist in DNA and RNA extraction. The company also offers TruArray tests for multiplexed molecular diagnostics, which analyze clinical samples such as blood, saliva, and urine. Akonni's technology is utilized in diagnosing a range of conditions, including infectious diseases, oncology, and genetic disorders. Their innovative systems leverage advanced methods like 3D gel drop microarray technology for effective detection of various health-related targets.

OriGene Technologies, Inc. is a biotechnology company based in Rockville, Maryland, specializing in the development, manufacturing, and sale of genome-wide research and diagnostic products. Established in 1995, OriGene offers a comprehensive array of tools for academic, diagnostic, pharmaceutical, and biotech applications. Its product portfolio includes cDNA clones, shRNA and siRNA reagents, CRISPR/Cas9 genome editing tools, proteins, antibodies, and anatomic pathology products. Additionally, the company provides services such as gene synthesis, custom cloning, and assay development, supporting a variety of research areas including cancer biomarker research and stem cell research. OriGene's extensive resources aim to facilitate gene-based research, enabling researchers to validate antibodies and develop new drugs. The company's products are distributed globally through various channels, including online platforms.

Sequenom, Inc. is a life sciences company focused on developing and commercializing molecular diagnostics testing services primarily for the women's health and oncology markets. It offers a range of laboratory-developed tests (LDTs), including the MaterniT21 PLUS, a noninvasive prenatal test (NIPT) that detects fetal chromosomal abnormalities through maternal blood samples. Other key products include the MaterniT21 GENOME test for detecting genomic deletions or duplications, the HerediT cystic fibrosis carrier screening test, and the SensiGene fetal Rhesus D test for determining the RhD factor in pregnant women. Additionally, Sequenom provides microarray tests under the NextView brand and various carrier screening tests for specific genetic disorders. The company serves physicians and client laboratories, and it has collaborated with Recombine Inc. Founded in 1994, Sequenom is headquartered in San Diego, California, and operates as a subsidiary of Laboratory Corporation of America Holdings.